Key result
DOACs cut intracranial bleeding risk ~50% compared to warfarin with targeted reversal agents available.
This review provides practical guidance on the use, laboratory monitoring, and reversal of direct oral anticoagulants to address physician concerns regarding bleeding and reversibility.
Answers are grounded in this paper and cite their sources.
May guide DOAC selection amid bleeding concerns; extends evidence synthesis but leaves reversal outcomes open to prospective trials.
Millions of patients in the United States use anticoagulation for a variety of indications, such as the prevention of stroke in those with atrial fibrillation (AF) and the treatment and prevention of venous thrombosis. For over six decades warfarin was the only available oral anticoagulant, but now several DOACs are available and their use has become more prevalent in recent years. In spite of this increased use, many physicians remain reluctant to prescribe DOACs due to concerns about bleeding and reversibility.
No takes yet. Share an insight, caveat, or question.
Joppa et al. (2018) conducted a review in Atrial fibrillation and venous thromboembolism. Direct Oral Anticoagulants (DOACs) and Reversal Agents vs. Warfarin and Enoxaparin was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: